Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Issue Cover for Volume 8, Number 5—May 2002

Volume 8, Number 5—May 2002

[PDF - 2.74 MB - 96 pages]

Perspective

Evaluation in Nonhuman Primates of Vaccines against Ebola Virus [PDF - 348 KB - 5 pages]
T. W. Geisbert et al.

Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90% of cases in both humans and nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects in nonhuman primates of vaccine strategies that had protected mice or guinea pigs from lethal EBOV infection. The following immunogens were used: RNA replicon particles derived from an attenuated strain of Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein and nucleoprotein; recombinant Vaccinia virus expressing EBOV glycoprotein; liposomes containing lipid A and inactivated EBOV; and a concentrated, inactivated whole-virion preparation. None of these strategies successfully protected nonhuman primates from robust challenge with EBOV. The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms.

EID Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in Nonhuman Primates of Vaccines against Ebola Virus. Emerg Infect Dis. 2002;8(5):503-507. https://doi.org/10.3201/eid0805.010284
AMA Geisbert TW, Pushko P, Anderson K, et al. Evaluation in Nonhuman Primates of Vaccines against Ebola Virus. Emerging Infectious Diseases. 2002;8(5):503-507. doi:10.3201/eid0805.010284.
APA Geisbert, T. W., Pushko, P., Anderson, K., Smith, J., Davis, K. J., & Jahrling, P. B. (2002). Evaluation in Nonhuman Primates of Vaccines against Ebola Virus. Emerging Infectious Diseases, 8(5), 503-507. https://doi.org/10.3201/eid0805.010284.
Synopses

Typical and Atypical Enteropathogenic Escherichia coli [PDF - 691 KB - 6 pages]
L. R. Trabulsi et al.

Typical and atypical enteropathogenic Escherichia coli (EPEC) strains differ in several characteristics. Typical EPEC, a leading cause of infantile diarrhea in developing countries, is rare in industrialized countries, where atypical EPEC seems to be a more important cause of diarrhea. For typical EPEC, the only reservoir is humans; for atypical EPEC, both animals and humans can be reservoirs. Typical and atypical EPEC also differ in genetic characteristics, serotypes, and virulence properties. Atypical EPEC is more closely related to Shiga toxin–producing E. coli (STEC), and like STEC these strains appear to be emerging pathogens.

EID Trabulsi LR, Keller R, Gomes TA. Typical and Atypical Enteropathogenic Escherichia coli. Emerg Infect Dis. 2002;8(5):508-513. https://doi.org/10.3201/eid0805.010385
AMA Trabulsi LR, Keller R, Gomes TA. Typical and Atypical Enteropathogenic Escherichia coli. Emerging Infectious Diseases. 2002;8(5):508-513. doi:10.3201/eid0805.010385.
APA Trabulsi, L. R., Keller, R., & Gomes, T. A. (2002). Typical and Atypical Enteropathogenic Escherichia coli. Emerging Infectious Diseases, 8(5), 508-513. https://doi.org/10.3201/eid0805.010385.
Research

Risk to Human Health from a Plethora of Simian Immunodeficiency Viruses in Primate Bushmeat [PDF - 627 KB - 7 pages]
M. Peeters et al.

To assess human exposure to Simian immunodeficiency virus (SIV) in west central Africa, we looked for SIV infection in 788 monkeys that were hunted in the rainforests of Cameroon for bushmeat or kept as pets. Serologic reactivity suggesting SIV infection was found in 13 of 16 primate species, including 4 not previously known to harbor SIV. Overall, 131 sera (16.6%) reacted strongly and an additional 34 (4.3%) reacted weakly with HIV antigens. Molecular analysis identified five new phylogenetic SIV lineages. These data document for the first time that a substantial proportion of wild monkeys in Cameroon are SIV infected and that humans who hunt and handle bushmeat are exposed to a plethora of genetically highly divergent viruses.

EID Peeters M, Courgnaud V, Abela B, Auzel P, Pourrut X, Bibollet-Ruche F, et al. Risk to Human Health from a Plethora of Simian Immunodeficiency Viruses in Primate Bushmeat. Emerg Infect Dis. 2002;8(5):451-457. https://doi.org/10.3201/eid0805.010522
AMA Peeters M, Courgnaud V, Abela B, et al. Risk to Human Health from a Plethora of Simian Immunodeficiency Viruses in Primate Bushmeat. Emerging Infectious Diseases. 2002;8(5):451-457. doi:10.3201/eid0805.010522.
APA Peeters, M., Courgnaud, V., Abela, B., Auzel, P., Pourrut, X., Bibollet-Ruche, F....Delaporte, E. (2002). Risk to Human Health from a Plethora of Simian Immunodeficiency Viruses in Primate Bushmeat. Emerging Infectious Diseases, 8(5), 451-457. https://doi.org/10.3201/eid0805.010522.

Epidemiology of Urban Canine Rabies, Santa Cruz, Bolivia, 1972–1997 [PDF - 230 KB - 4 pages]
M. Widdowson et al.

We analyzed laboratory data from 1972 to 1997 from Santa Cruz, Bolivia, to determine risk factors for laboratory canine samples’ testing positive for Rabies virus (RABV). Of 9,803 samples, 50.7% tested positive for RABV; the number of cases and the percentage positive has dropped significantly since 1978. A 5- to 6-year cycle in rabies incidence was clearly apparent, though no seasonality was noted. Male dogs had significantly increased odds of testing positive for RABV (odds ratio [OR]=1.14), as did 1- to 2-year-old dogs (OR=1.73); younger and older dogs were at lower risk. Samples submitted from the poorer suburbs of the city were more likely to test positive for RABV (OR=1.71). We estimated the distribution of endemic canine rabies in an urban environment to facilitate control measures in a resource-poor environment.

EID Widdowson M, Morales GJ, Chaves S, McGrane J. Epidemiology of Urban Canine Rabies, Santa Cruz, Bolivia, 1972–1997. Emerg Infect Dis. 2002;8(5):458-461. https://doi.org/10.3201/eid0805.010302
AMA Widdowson M, Morales GJ, Chaves S, et al. Epidemiology of Urban Canine Rabies, Santa Cruz, Bolivia, 1972–1997. Emerging Infectious Diseases. 2002;8(5):458-461. doi:10.3201/eid0805.010302.
APA Widdowson, M., Morales, G. J., Chaves, S., & McGrane, J. (2002). Epidemiology of Urban Canine Rabies, Santa Cruz, Bolivia, 1972–1997. Emerging Infectious Diseases, 8(5), 458-461. https://doi.org/10.3201/eid0805.010302.

Clonal Groupings in Serogroup X Neisseria meningitidis [PDF - 491 KB - 5 pages]
S. Gagneux et al.

The genetic diversity of 134 serogroup X Neisseria meningitis isolates from Africa, Europe, and North America was analyzed by multilocus sequence typing and pulsed-field gel electrophoresis. Although most European and American isolates were highly diverse, one clonal grouping was identified in sporadic disease and carrier strains isolated over the last 2 decades in the United Kingdom, the Netherlands, Germany, and the United States. In contrast to the diversity in the European and American isolates, most carrier and disease isolates recovered during the last 30 years in countries in the African meningitis belt belonged to a second clonal grouping. During the last decade, these bacteria have caused meningitis outbreaks in Niger and Ghana. These results support the development of a comprehensive conjugate vaccine that would include serogroup X polysaccharide.

EID Gagneux S, Wirth T, Hodgson A, Ehrhard I, Morelli G, Kriz P, et al. Clonal Groupings in Serogroup X Neisseria meningitidis. Emerg Infect Dis. 2002;8(5):462-466. https://doi.org/10.3201/eid0805.010227
AMA Gagneux S, Wirth T, Hodgson A, et al. Clonal Groupings in Serogroup X Neisseria meningitidis. Emerging Infectious Diseases. 2002;8(5):462-466. doi:10.3201/eid0805.010227.
APA Gagneux, S., Wirth, T., Hodgson, A., Ehrhard, I., Morelli, G., Kriz, P....Achtman, M. (2002). Clonal Groupings in Serogroup X Neisseria meningitidis. Emerging Infectious Diseases, 8(5), 462-466. https://doi.org/10.3201/eid0805.010227.

Genetic Variants of Ehrlichia phagocytophila, Rhode Island and Connecticut [PDF - 222 KB - 7 pages]
R. F. Massung et al.

Primers were used to amplify a 561-bp region of the 16S rRNA gene of Ehrlichia phagocytophila from Ixodes scapularis ticks and small mammals collected in Rhode Island and Connecticut. DNA sequences for all 50 E. phagocytophila-positive samples collected from 1996 through 1998 in southwestern Connecticut were identical to the sequence reported for E. phagocytophila DNA from confirmed human cases. In contrast, the sequences from 92 of 123 E. phagocytophila-positive Rhode Island samples collected from 1996 through 1999 included several variants differing by 1-2 nucleotides from that in the agent infecting humans. While 11.9% of 67 E. phagocytophila-positive ticks collected during 1997 in Rhode Island harbored ehrlichiae with sequences identical to that of the human agent, 79.1% had a variant sequence not previously described. The low incidence of human ehrlichiosis in Rhode Island may in part result from interference by these variant ehrlichiae with maintenance and transmission of the true agent of human disease.

EID Massung RF, Mauel MJ, Owens JH, Allan N, Courtney JW, Stafford KC, et al. Genetic Variants of Ehrlichia phagocytophila, Rhode Island and Connecticut. Emerg Infect Dis. 2002;8(5):467-472. https://doi.org/10.3201/eid0805.010251
AMA Massung RF, Mauel MJ, Owens JH, et al. Genetic Variants of Ehrlichia phagocytophila, Rhode Island and Connecticut. Emerging Infectious Diseases. 2002;8(5):467-472. doi:10.3201/eid0805.010251.
APA Massung, R. F., Mauel, M. J., Owens, J. H., Allan, N., Courtney, J. W., Stafford, K. C....Mather, T. N. (2002). Genetic Variants of Ehrlichia phagocytophila, Rhode Island and Connecticut. Emerging Infectious Diseases, 8(5), 467-472. https://doi.org/10.3201/eid0805.010251.

Trends in Fluoroquinolone (Ciprofloxacin) Resistance in Enterobacteriaceae from Bacteremias, England and Wales, 1990–1999 [PDF - 310 KB - 6 pages]
D. M. Livermore et al.

The Public Health Laboratory Service receives antibiotic susceptibility data for bacteria from bloodstream infections from most hospitals in England and Wales. These data were used to ascertain resistance trends to ciprofloxacin from 1990 through 1999 for the most prevalent gram-negative agents: Escherichia coli, Klebsiella spp., Enterobacter spp., and Proteus mirabilis. Significant increases in resistance were observed for all four species groups. For E. coli, ciprofloxacin resistance rose from 0.8% in 1990 to 3.7% in 1999 and became widely scattered among reporting hospitals. The prevalence of resistance in Klebsiella spp. rose from 3.5% in 1990, to 9.5% in 1996 and 7.1% in 1999, while that in Enterobacter spp. rose from 2.1% in 1990 to 10.5% in 1996 and 10.9% in 1999. For both Klebsiella and Enterobacter spp., most resistance was localized in a few centers. Resistance was infrequent and scattered in P. mirabilis, but reached a prevalence of 3.3% in 1999.

EID Livermore DM, James D, Reacher M, Graham C, Nichols T, Stephens P, et al. Trends in Fluoroquinolone (Ciprofloxacin) Resistance in Enterobacteriaceae from Bacteremias, England and Wales, 1990–1999. Emerg Infect Dis. 2002;8(5):473-478. https://doi.org/10.3201/eid0805.010204
AMA Livermore DM, James D, Reacher M, et al. Trends in Fluoroquinolone (Ciprofloxacin) Resistance in Enterobacteriaceae from Bacteremias, England and Wales, 1990–1999. Emerging Infectious Diseases. 2002;8(5):473-478. doi:10.3201/eid0805.010204.
APA Livermore, D. M., James, D., Reacher, M., Graham, C., Nichols, T., Stephens, P....George, R. C. (2002). Trends in Fluoroquinolone (Ciprofloxacin) Resistance in Enterobacteriaceae from Bacteremias, England and Wales, 1990–1999. Emerging Infectious Diseases, 8(5), 473-478. https://doi.org/10.3201/eid0805.010204.

Nasopharyngeal Carriage of Streptococcus pneumoniae in Healthy Children: Implications for the Use of Heptavalent Pnemococcal Conjugate Vaccine [PDF - 240 KB - 6 pages]
P. Marchisio et al.

We assessed the prevalence of Streptococcus pneumoniae serotypes in the nasopharynx of healthy children, antimicrobial susceptibility patterns, risk factors for carriage, and the coverage of heptavalent pneumococcal conjugate vaccine. In 2,799 healthy infants and children, the S. pneumoniae carrier rate was 8.6% (serotypes 3, 19F, 23F, 19A, 6B, and 14 were most common). Most pneumococci (69.4%) were resistant to one or more antimicrobial classes. The rate of penicillin resistance was low (9.1%); macrolide resistance was high (52.1%). Overall, 63.2% of the isolates belonged to strains covered by the heptavalent pneumococcal vaccine. This percentage was higher in children <2 years old (73.1%) and in those >2-5 years old(68.9%). Sinusitis in the previous 3 months was the only risk factor for carrier status; acute otitis media was the only risk factor for the carriage of penicillin-resistant S. pneumoniae. Most the isolated strains are covered by the heptavalent conjugate vaccine, especially in the first years of life, suggesting that its use could reduce the incidence of pneumococcal disease.

EID Marchisio P, Esposito S, Schito G, Marchese A, Cavagna R, Principi N. Nasopharyngeal Carriage of Streptococcus pneumoniae in Healthy Children: Implications for the Use of Heptavalent Pnemococcal Conjugate Vaccine. Emerg Infect Dis. 2002;8(5):479-484. https://doi.org/10.3201/eid0805.010235
AMA Marchisio P, Esposito S, Schito G, et al. Nasopharyngeal Carriage of Streptococcus pneumoniae in Healthy Children: Implications for the Use of Heptavalent Pnemococcal Conjugate Vaccine. Emerging Infectious Diseases. 2002;8(5):479-484. doi:10.3201/eid0805.010235.
APA Marchisio, P., Esposito, S., Schito, G., Marchese, A., Cavagna, R., & Principi, N. (2002). Nasopharyngeal Carriage of Streptococcus pneumoniae in Healthy Children: Implications for the Use of Heptavalent Pnemococcal Conjugate Vaccine. Emerging Infectious Diseases, 8(5), 479-484. https://doi.org/10.3201/eid0805.010235.

Hospital-based Diagnosis of Hemorrhagic Fever, Encephalitis, and Hepatitis in Cambodian Children [PDF - 840 KB - 5 pages]
Y. M. Chhour et al.

Surveillance was conducted for three clinical syndromes (hemorrhagic fever, encephalitis, and hepatitis) in Cambodian children admitted to the National Pediatric Hospital in Phnom Penh from July 1996 through September 1998. Acute- and convalescent-phase sera, and cerebrospinal fluid, when applicable, underwent diagnostic evaluation for infections with Dengue virus (DENV), Japanese encephalitis virus (JEV), and Hepatitis A, B, C, and E viruses. Of 621 children admitted with hemorrhagic fever, 499 (80%) were confirmed to have either primary or secondary DENV infection. DENV rates were as high as 10.6/100 hospital admissions in September 1998. Of 50 children with clinical encephalitis, 9 (18%) had serologic evidence of JEV infection. Forty-four children had clinical hepatitis, most (55%) due to Hepatitis A virus (HAV). One patient had Hepatitis B virus, and no patients had hepatitis C or E. This study identified a large number of children with vaccine-preventable diseases (JEV and HAV).

EID Chhour YM, Ruble G, Hong R, Minn K, Kdan Y, Sok T, et al. Hospital-based Diagnosis of Hemorrhagic Fever, Encephalitis, and Hepatitis in Cambodian Children. Emerg Infect Dis. 2002;8(5):485-489. https://doi.org/10.3201/eid0805.010236
AMA Chhour YM, Ruble G, Hong R, et al. Hospital-based Diagnosis of Hemorrhagic Fever, Encephalitis, and Hepatitis in Cambodian Children. Emerging Infectious Diseases. 2002;8(5):485-489. doi:10.3201/eid0805.010236.
APA Chhour, Y. M., Ruble, G., Hong, R., Minn, K., Kdan, Y., Sok, T....Endy, T. P. (2002). Hospital-based Diagnosis of Hemorrhagic Fever, Encephalitis, and Hepatitis in Cambodian Children. Emerging Infectious Diseases, 8(5), 485-489. https://doi.org/10.3201/eid0805.010236.

Excess Mortality Associated with Antimicrobial Drug-Resistant Salmonella Typhimurium [PDF - 229 KB - 6 pages]
M. Helms et al.

In a matched cohort study, we determined the death rates associated with drug resistance in Salmonella Typhimurium. We linked data from the Danish Surveillance Registry for Enteric Pathogens with the Civil Registration System and the Danish National Discharge Registry. By survival analysis, the 2-year death rates were compared with a matched sample of the general Danish population, after the data were adjusted for differences in comorbidity. In 2,047 patients with S. Typhimurium, 59 deaths were identified. Patients with pansusceptible strains of S. Typhimurium were 2.3 times more likely to die 2 years after infection than persons in the general Danish population. Patients infected with strains resistant to ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline were 4.8 times (95% CI 2.2 to 10.2) more likely to die, whereas quinolone resistance was associated with a mortality rate 10.3 times higher than the general population.

EID Helms M, Vastrup P, Gerner-Smidt P, Mølbak K. Excess Mortality Associated with Antimicrobial Drug-Resistant Salmonella Typhimurium. Emerg Infect Dis. 2002;8(5):490-495. https://doi.org/10.3201/eid0805.010267
AMA Helms M, Vastrup P, Gerner-Smidt P, et al. Excess Mortality Associated with Antimicrobial Drug-Resistant Salmonella Typhimurium. Emerging Infectious Diseases. 2002;8(5):490-495. doi:10.3201/eid0805.010267.
APA Helms, M., Vastrup, P., Gerner-Smidt, P., & Mølbak, K. (2002). Excess Mortality Associated with Antimicrobial Drug-Resistant Salmonella Typhimurium. Emerging Infectious Diseases, 8(5), 490-495. https://doi.org/10.3201/eid0805.010267.

Sentinel Surveillance: A Reliable Way To Track Antibiotic Resistance in Communities? [PDF - 258 KB - 7 pages]
S. J. Schrag et al.

We used population-based data to evaluate how often groups of randomly selected clinical laboratories accurately estimated the prevalence of resistant pneumococci and captured trends in resistance over time. Surveillance for invasive pneumococcal disease was conducted in eight states from 1996 to 1998. Within each surveillance area, we evaluated the proportion of all groups of three, four, and five laboratories that estimated the prevalence of penicillin-nonsusceptible pneumococci (%PNSP) and the change in %PNSP over time. We assessed whether sentinel groups detected emerging fluoroquinolone resistance. Groups of five performed best. Sentinel groups accurately predicted %PNSP in five states; states where they performed poorly had high between-laboratory variation in %PNSP. Sentinel groups detected large changes in prevalence of nonsusceptibility over time but rarely detected emerging fluoroquinolone resistance. Characteristics of hospital-affiliated laboratories were not useful predictors of a laboratory’s %PNSP. Sentinel surveillance for resistant pneumococci can detect important trends over time but rarely detects newly emerging resistance profiles.

EID Schrag SJ, Zell ER, Schuchat A, Whitney CG. Sentinel Surveillance: A Reliable Way To Track Antibiotic Resistance in Communities?. Emerg Infect Dis. 2002;8(5):496-502. https://doi.org/10.3201/eid0805.010268
AMA Schrag SJ, Zell ER, Schuchat A, et al. Sentinel Surveillance: A Reliable Way To Track Antibiotic Resistance in Communities?. Emerging Infectious Diseases. 2002;8(5):496-502. doi:10.3201/eid0805.010268.
APA Schrag, S. J., Zell, E. R., Schuchat, A., & Whitney, C. G. (2002). Sentinel Surveillance: A Reliable Way To Track Antibiotic Resistance in Communities?. Emerging Infectious Diseases, 8(5), 496-502. https://doi.org/10.3201/eid0805.010268.
Dispatches

Increasing Quinolone Resistance in Salmonella enterica serotype Enteritidis [PDF - 176 KB - 2 pages]
K. Mølbak et al.

Until recently, Salmonella enterica serotype Enteritidis has remained sensitive to most antibiotics. However, national surveillance data from Denmark show that quinolone resistance in S. Enteritidis has increased from 0.8% in 1995 to 8.5% in 2000. These data support concerns that the current use of quinolone in food animals leads to increasing resistance in S. Enteritidis and that action should be taken to limit such use.

EID Mølbak K, Gerner-Smidt P, Wegener HC. Increasing Quinolone Resistance in Salmonella enterica serotype Enteritidis. Emerg Infect Dis. 2002;8(5):514-515. https://doi.org/10.3201/eid0805.010288
AMA Mølbak K, Gerner-Smidt P, Wegener HC. Increasing Quinolone Resistance in Salmonella enterica serotype Enteritidis. Emerging Infectious Diseases. 2002;8(5):514-515. doi:10.3201/eid0805.010288.
APA Mølbak, K., Gerner-Smidt, P., & Wegener, H. C. (2002). Increasing Quinolone Resistance in Salmonella enterica serotype Enteritidis. Emerging Infectious Diseases, 8(5), 514-515. https://doi.org/10.3201/eid0805.010288.

Molecular Characterization of Corynebacterium diphtheriae isolates, Russia, 1957–1987 [PDF - 330 KB - 3 pages]
V. Skogen et al.

In the 1990s, the Newly Independent and Baltic States of the former Soviet Union experienced the largest diphtheria outbreak since the 1960s; it was caused by Corynebacterium diphtheriae strains of a unique clonal group. To address its origin, we studied 47 clinical isolates from Russia and demonstrated that this clonal group was an integral part of the endemic reservoir that existed in Russia at least 5 years before the epidemic began.

EID Skogen V, Cherkasova VV, Maksimova N, Marston CK, Sjursen H, Reeves MW, et al. Molecular Characterization of Corynebacterium diphtheriae isolates, Russia, 1957–1987. Emerg Infect Dis. 2002;8(5):516-518. https://doi.org/10.3201/eid0805.010276
AMA Skogen V, Cherkasova VV, Maksimova N, et al. Molecular Characterization of Corynebacterium diphtheriae isolates, Russia, 1957–1987. Emerging Infectious Diseases. 2002;8(5):516-518. doi:10.3201/eid0805.010276.
APA Skogen, V., Cherkasova, V. V., Maksimova, N., Marston, C. K., Sjursen, H., Reeves, M. W....Popovic, T. (2002). Molecular Characterization of Corynebacterium diphtheriae isolates, Russia, 1957–1987. Emerging Infectious Diseases, 8(5), 516-518. https://doi.org/10.3201/eid0805.010276.

Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada [PDF - 312 KB - 3 pages]
G. J. Tyrrell et al.

From December 1999 to April 2001, the greater Edmonton region had 61 cases of invasive meningococcal infection, two fatal. The outbreak was due to Neisseria meningitidis serogroup C, electrophoretic type 15, serotype 2a. Analysis of the strains showed that 50 of 56 culture-confirmed cases were due to a single clone and close relatives of this clone. This strain had not been previously identified in the province of Alberta dating back to January 1997

EID Tyrrell GJ, Chui L, Johnson M, Chang N, Rennie RP, Talbot JA. Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada. Emerg Infect Dis. 2002;8(5):519-521. https://doi.org/10.3201/eid0805.010337
AMA Tyrrell GJ, Chui L, Johnson M, et al. Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada. Emerging Infectious Diseases. 2002;8(5):519-521. doi:10.3201/eid0805.010337.
APA Tyrrell, G. J., Chui, L., Johnson, M., Chang, N., Rennie, R. P., & Talbot, J. A. (2002). Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada. Emerging Infectious Diseases, 8(5), 519-521. https://doi.org/10.3201/eid0805.010337.

Cefepime MIC as a Predictor of the Extended-Spectrum β-Lactamase Type in Klebsiella pneumoniae, Taiwan [PDF - 155 KB - 3 pages]
W. L. Yu et al.

To guide selection of carbapenems or fourth-generation cephalosporins as therapy, 110 Klebsiella pneumoniae isolates with extended-spectrum β-lactamases from Taiwan were characterized by phenotypic (MICs), molecular, and chemical methods. MIC patterns of ceftazidime and cefepime clearly differentiate strains treatable by cefepime and those capable of efficiently hydrolyzing available cephalosporins (CTX-M series and SHV-types). Continued use of cefepime appears to be a treatment option in cases for which MIC results are available and interpreted by the criteria presented.

EID Yu WL, Pfaller MA, Winokur PL, Jones RN. Cefepime MIC as a Predictor of the Extended-Spectrum β-Lactamase Type in Klebsiella pneumoniae, Taiwan. Emerg Infect Dis. 2002;8(5):522-524. https://doi.org/10.3201/eid0805.010346
AMA Yu WL, Pfaller MA, Winokur PL, et al. Cefepime MIC as a Predictor of the Extended-Spectrum β-Lactamase Type in Klebsiella pneumoniae, Taiwan. Emerging Infectious Diseases. 2002;8(5):522-524. doi:10.3201/eid0805.010346.
APA Yu, W. L., Pfaller, M. A., Winokur, P. L., & Jones, R. N. (2002). Cefepime MIC as a Predictor of the Extended-Spectrum β-Lactamase Type in Klebsiella pneumoniae, Taiwan. Emerging Infectious Diseases, 8(5), 522-524. https://doi.org/10.3201/eid0805.010346.

Deer Meat as the Source for a Sporadic Case of Escherichia coli O157:H7 Infection, Connecticut [PDF - 373 KB - 3 pages]
T. Rabatsky-Ehr et al.

We report a case of Escherichia coli O157:H7, which was acquired by eating wild White-Tailed deer (Odocoileus virginianus). DNA fingerprint analysis verified venison as the source of infection. This pediatric case emphasizes the need for dissemination of information to hunters regarding the safe handling and processing of venison.

EID Rabatsky-Ehr T, Dingman D, Marcus R, Howard R, Kinney A, Mshar P. Deer Meat as the Source for a Sporadic Case of Escherichia coli O157:H7 Infection, Connecticut. Emerg Infect Dis. 2002;8(5):525-527. https://doi.org/10.3201/eid0805.010373
AMA Rabatsky-Ehr T, Dingman D, Marcus R, et al. Deer Meat as the Source for a Sporadic Case of Escherichia coli O157:H7 Infection, Connecticut. Emerging Infectious Diseases. 2002;8(5):525-527. doi:10.3201/eid0805.010373.
APA Rabatsky-Ehr, T., Dingman, D., Marcus, R., Howard, R., Kinney, A., & Mshar, P. (2002). Deer Meat as the Source for a Sporadic Case of Escherichia coli O157:H7 Infection, Connecticut. Emerging Infectious Diseases, 8(5), 525-527. https://doi.org/10.3201/eid0805.010373.

Phylogenetic Analysis of a Human Isolate from the 2000 Israel West Nile virus Epidemic [PDF - 180 KB - 4 pages]
T. Briese et al.

Specimens from a patient of the 2000 Israel West Nile virus epidemic were analyzed by reverse transcription-polymerase chain reaction. Products corresponding to E, NS3, and NS5 sequences were amplified from cerebellar but not from cortical samples. Phylogenetic analyses indicated a closer relationship of this isolate to 1996 Romanian and 1999 Russian than to 1998-99 Israeli or 1999 New York isolates.

EID Briese T, Rambaut A, Pathmajeyan M, Bishara J, Weinberger M, Pitlik S, et al. Phylogenetic Analysis of a Human Isolate from the 2000 Israel West Nile virus Epidemic. Emerg Infect Dis. 2002;8(5):528-531. https://doi.org/10.3201/eid0805.010324
AMA Briese T, Rambaut A, Pathmajeyan M, et al. Phylogenetic Analysis of a Human Isolate from the 2000 Israel West Nile virus Epidemic. Emerging Infectious Diseases. 2002;8(5):528-531. doi:10.3201/eid0805.010324.
APA Briese, T., Rambaut, A., Pathmajeyan, M., Bishara, J., Weinberger, M., Pitlik, S....Lipkin, W. (2002). Phylogenetic Analysis of a Human Isolate from the 2000 Israel West Nile virus Epidemic. Emerging Infectious Diseases, 8(5), 528-531. https://doi.org/10.3201/eid0805.010324.

Knowledge of Bat Rabies and Human Exposure Among United States Cavers [PDF - 570 KB - 3 pages]
R. V. Gibbons et al.

We surveyed cavers who attended the National Speleological Society convention in June 2000. Fifteen percent of respondents did not consider a bat bite a risk for acquiring rabies; only 20% had received preexposure prophylaxis against the disease. An under-appreciation of the risk for rabies from bat bites may explain the preponderance of human rabies viruses caused by variant strains associated with bats in the United States.

EID Gibbons RV, Holman RC, Mosberg SR, Rupprecht CE. Knowledge of Bat Rabies and Human Exposure Among United States Cavers. Emerg Infect Dis. 2002;8(5):532-534. https://doi.org/10.3201/eid0805.010290
AMA Gibbons RV, Holman RC, Mosberg SR, et al. Knowledge of Bat Rabies and Human Exposure Among United States Cavers. Emerging Infectious Diseases. 2002;8(5):532-534. doi:10.3201/eid0805.010290.
APA Gibbons, R. V., Holman, R. C., Mosberg, S. R., & Rupprecht, C. E. (2002). Knowledge of Bat Rabies and Human Exposure Among United States Cavers. Emerging Infectious Diseases, 8(5), 532-534. https://doi.org/10.3201/eid0805.010290.
Letters

First Shiga Toxin-Producing Escherichia coli Isolate from a Patient with Hemolytic Uremic Syndrome, Brazil [PDF - 145 KB - 2 pages]
B. E. Guth et al.
EID Guth BE, Lopes de Souza R, Vaz TM, Irino K. First Shiga Toxin-Producing Escherichia coli Isolate from a Patient with Hemolytic Uremic Syndrome, Brazil. Emerg Infect Dis. 2002;8(5):535-536. https://doi.org/10.3201/eid0805.010419
AMA Guth BE, Lopes de Souza R, Vaz TM, et al. First Shiga Toxin-Producing Escherichia coli Isolate from a Patient with Hemolytic Uremic Syndrome, Brazil. Emerging Infectious Diseases. 2002;8(5):535-536. doi:10.3201/eid0805.010419.
APA Guth, B. E., Lopes de Souza, R., Vaz, T. M., & Irino, K. (2002). First Shiga Toxin-Producing Escherichia coli Isolate from a Patient with Hemolytic Uremic Syndrome, Brazil. Emerging Infectious Diseases, 8(5), 535-536. https://doi.org/10.3201/eid0805.010419.

Emergence of Vancomycin-Intermediate Staphylococcus aureus and S. sciuri, Greece [PDF - 140 KB - 2 pages]
A. Tsakris et al.
EID Tsakris A, Papadimitriou E, Douboyas J, Stylianopoulou F, Manolis E. Emergence of Vancomycin-Intermediate Staphylococcus aureus and S. sciuri, Greece. Emerg Infect Dis. 2002;8(5):536-537. https://doi.org/10.3201/eid0805.010387
AMA Tsakris A, Papadimitriou E, Douboyas J, et al. Emergence of Vancomycin-Intermediate Staphylococcus aureus and S. sciuri, Greece. Emerging Infectious Diseases. 2002;8(5):536-537. doi:10.3201/eid0805.010387.
APA Tsakris, A., Papadimitriou, E., Douboyas, J., Stylianopoulou, F., & Manolis, E. (2002). Emergence of Vancomycin-Intermediate Staphylococcus aureus and S. sciuri, Greece. Emerging Infectious Diseases, 8(5), 536-537. https://doi.org/10.3201/eid0805.010387.
Books and Media

Acute Respiratory Infection CD Module [PDF - 103 KB - 1 page]
P. L. Riley et al.
EID Riley PL, Downes EA, Chikomo MP. Acute Respiratory Infection CD Module. Emerg Infect Dis. 2002;8(5):538. https://doi.org/10.3201/eid0805.020024
AMA Riley PL, Downes EA, Chikomo MP. Acute Respiratory Infection CD Module. Emerging Infectious Diseases. 2002;8(5):538. doi:10.3201/eid0805.020024.
APA Riley, P. L., Downes, E. A., & Chikomo, M. P. (2002). Acute Respiratory Infection CD Module. Emerging Infectious Diseases, 8(5), 538. https://doi.org/10.3201/eid0805.020024.
Corrections

Correction, Vol. 8, No. 1 [PDF - 15 KB - 1 page]
EID Correction, Vol. 8, No. 1. Emerg Infect Dis. 2002;8(5):540. https://doi.org/10.3201/eid0805.c10805
AMA Correction, Vol. 8, No. 1. Emerging Infectious Diseases. 2002;8(5):540. doi:10.3201/eid0805.c10805.
APA (2002). Correction, Vol. 8, No. 1. Emerging Infectious Diseases, 8(5), 540. https://doi.org/10.3201/eid0805.c10805.

Correction, Vol. 8, No. 2 [PDF - 15 KB - 1 page]
EID Correction, Vol. 8, No. 2. Emerg Infect Dis. 2002;8(5):540. https://doi.org/10.3201/eid0805.c20805
AMA Correction, Vol. 8, No. 2. Emerging Infectious Diseases. 2002;8(5):540. doi:10.3201/eid0805.c20805.
APA (2002). Correction, Vol. 8, No. 2. Emerging Infectious Diseases, 8(5), 540. https://doi.org/10.3201/eid0805.c20805.

Correction, Vol. 8, No. 4 [PDF - 15 KB - 1 page]
EID Correction, Vol. 8, No. 4. Emerg Infect Dis. 2002;8(5):540. https://doi.org/10.3201/eid0805.c30805
AMA Correction, Vol. 8, No. 4. Emerging Infectious Diseases. 2002;8(5):540. doi:10.3201/eid0805.c30805.
APA (2002). Correction, Vol. 8, No. 4. Emerging Infectious Diseases, 8(5), 540. https://doi.org/10.3201/eid0805.c30805.

Correction, Vol. 8, No. 4 [PDF - 15 KB - 1 page]
EID Correction, Vol. 8, No. 4. Emerg Infect Dis. 2002;8(5):540. https://doi.org/10.3201/eid0805.c40805
AMA Correction, Vol. 8, No. 4. Emerging Infectious Diseases. 2002;8(5):540. doi:10.3201/eid0805.c40805.
APA (2002). Correction, Vol. 8, No. 4. Emerging Infectious Diseases, 8(5), 540. https://doi.org/10.3201/eid0805.c40805.
About the Cover

Fable, c. 1600 [PDF - 24 KB - 1 page]
P. Potter
EID Potter P. Fable, c. 1600. Emerg Infect Dis. 2002;8(5):541. https://doi.org/10.3201/eid0805.ac0805
AMA Potter P. Fable, c. 1600. Emerging Infectious Diseases. 2002;8(5):541. doi:10.3201/eid0805.ac0805.
APA Potter, P. (2002). Fable, c. 1600. Emerging Infectious Diseases, 8(5), 541. https://doi.org/10.3201/eid0805.ac0805.
Page created: June 28, 2012
Page updated: June 28, 2012
Page reviewed: June 28, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
edit_01 ScholarOne Submission Portal
Issue Select
GO
GO

Spotlight Topics

 

 

Get Email Updates

To receive email updates about this page, enter your email address:

file_external